REPLIGEN CORPORATION Reports 23.3% Decrease in Total Revenue for Q2 2023

August 28, 2023

🌥️Earnings Overview

REPLIGEN CORPORATION ($NASDAQ:RGEN) reported total revenue of USD 159.2 million for the quarter ending June 30 2023, a decrease of 23.3% from the same period the prior fiscal year. Furthermore, net income for the second quarter decreased by 59.8%, amounting to USD 20.1 million.


GoodWhale recently conducted an extensive analysis of REPLIGEN CORPORATION‘s wellbeing. According to Risk Rating, REPLIGEN CORPORATION is a high risk investment in terms of financial and business aspects. GoodWhale has detected 3 risk warnings in the company’s income sheet, balance sheet, and cashflow statement. They have identified potential risks that could lead to a loss of funds for investors. To help protect potential investors from financial losses, GoodWhale has made all of their findings and research available on their website. Those interested in REPLIGEN CORPORATION’s financial performance can easily register on to check it out. GoodWhale provides comprehensive analyses of companies of all sizes and sectors, making it an invaluable resource for investors and other stakeholders. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Repligen Corporation. More…

    Total Revenues Net Income Net Margin
    729.33 138.03 14.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Repligen Corporation. More…

    Operations Investing Financing
    160.12 -233.24 -13.34
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Repligen Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    2.55k 578.08 34.85
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Repligen Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    34.1% 44.2% 22.3%
    FCF Margin ROE ROA
    6.2% 5.2% 4.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s products include proteins and antibodies for the treatment of cancer, central nervous system disorders, and infectious diseases. ReGen Biologics Inc, Tecan Group AG, Stevanato Group SPA are all competitors in the market for developing and commercializing therapeutics.

    – ReGen Biologics Inc ($OTCPK:RGBOQ)

    Regen Biologics, Inc. is a biotechnology company, which focuses on the development, commercialization, and marketing of products in the orthopedic regenerative medicine field. The company’s products include collagen-based scaffolds for use in orthopedic and sports medicine indications. It operates in the United States, Europe, and Asia. The company was founded by David A. Jay and Stephen J. Sacks in 1997 and is headquartered in Laguna Niguel, CA.

    – Tecan Group AG ($OTCPK:TCHBF)

    Tecan Group AG is a Swiss-based manufacturer of laboratory instruments and solutions for the life sciences sector. The company has a market cap of 4.54B as of December 2020 and a Return on Equity of 6.13%. Tecan Group AG’s products are used in academic and commercial research laboratories, as well as in clinical diagnostic laboratories. The company’s instruments are used for a variety of applications, including drug discovery and development, biopharmaceutical production, food safety testing, and environmental monitoring.

    – Stevanato Group SPA ($NYSE:STVN)

    Stevanato Group is a leading provider of integrated solutions for the pharmaceutical and biotech industry. The Group offers a complete range of services, from design and development to manufacturing and packaging of finished products. The Group’s products are used in a wide range of therapeutic areas, including cancer, immunology, infectious diseases and neurology.


    Investors should be wary of REPLIGEN CORPORATION as the company reported a significant decrease in revenue and net income for the quarter ending June 30 2023. Total revenue for the quarter was USD 159.2 million, a decrease of 23.3% compared to the same period in the previous fiscal year. Net income was USD 20.1 million, a decrease of 59.8%. Therefore, investors should take caution when considering investing in REPLIGEN CORPORATION as it may not be a viable or profitable investment option.

    Recent Posts

    Leave a Comment